QIPT vs. INNV, TALK, DCGO, CELC, EHAB, PSNL, VMD, AIRS, SERA, and LFMD
Should you be buying Quipt Home Medical stock or one of its competitors? The main competitors of Quipt Home Medical include InnovAge (INNV), Talkspace (TALK), DocGo (DCGO), Celcuity (CELC), Enhabit (EHAB), Personalis (PSNL), Viemed Healthcare (VMD), AirSculpt Technologies (AIRS), Sera Prognostics (SERA), and LifeMD (LFMD). These companies are all part of the "healthcare" industry.
Quipt Home Medical vs.
Quipt Home Medical (NASDAQ:QIPT) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Quipt Home Medical received 31 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 83.78% of users gave Quipt Home Medical an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
42.9% of Quipt Home Medical shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 4.2% of Quipt Home Medical shares are owned by insiders. Comparatively, 1.4% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Quipt Home Medical had 2 more articles in the media than InnovAge. MarketBeat recorded 3 mentions for Quipt Home Medical and 1 mentions for InnovAge. InnovAge's average media sentiment score of 0.96 beat Quipt Home Medical's score of 0.46 indicating that InnovAge is being referred to more favorably in the news media.
Quipt Home Medical has higher earnings, but lower revenue than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Quipt Home Medical, indicating that it is currently the more affordable of the two stocks.
Quipt Home Medical currently has a consensus target price of $6.25, indicating a potential upside of 106.95%. InnovAge has a consensus target price of $6.00, indicating a potential upside of 68.07%. Given Quipt Home Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Quipt Home Medical is more favorable than InnovAge.
InnovAge has a net margin of -2.03% compared to Quipt Home Medical's net margin of -2.66%. InnovAge's return on equity of -5.68% beat Quipt Home Medical's return on equity.
Quipt Home Medical has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.
Summary
Quipt Home Medical beats InnovAge on 13 of the 19 factors compared between the two stocks.
Get Quipt Home Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for QIPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quipt Home Medical Competitors List
Related Companies and Tools
This page (NASDAQ:QIPT) was last updated on 1/20/2025 by MarketBeat.com Staff
